ESCC
Conditions
Keywords
ESCC, SHR-1701, Retlirafusp alfa, Liposomal Irinotecan (II)
Brief summary
This study is a single-arm, exploratory clinical trial aimed at evaluating the efficacy and safety of SHR-1701 in combination with liposomal irinotecan (II) in patients with esophageal squamous cell carcinoma who have received prior immunotherapy. Eligible patients with esophageal cancer will be treated with SHR-1701 in combination with liposomal irinotecan (II).
Interventions
DRUGSHR-1701+ liposomal irinotecan (II)
SHR-1701 in combination with Irinotecan Liposome (II) is administered on Day 1 of each 3-week treatment cycle until disease progression, intolerable toxicity, withdrawal of consent, or a decision by the investigator to discontinue treatment, or until the maximum treatment duration of 2 years has been reached, whichever occurs first.
Sponsors
Zhigang Li
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed written informed consent, voluntarily participating in this study; 2. Histopathologically or cytologically confirmed esophageal squamous cell carcinoma; 3. Prior treatment with immunotherapy; 4. At least one measurable lesion as assessed by RECIST version 1.1; 5. Age ≥ 18 years, male or female; 6. ECOG performance status of 0 or 1; 7. Life expectancy \> 3 months; 8. Adequate organ function: 1. Hematology: Neutrophils ≥ 1.5 × 10\^9/L, Hemoglobin ≥ 9 g/dL, Platelets ≥ 100 × 10\^9/L. 2. Hepatic function: Bilirubin ≤ 1.5 × the upper limit of normal (ULN) (patients with known Gilbert's disease and serum bilirubin ≤ 3 × ULN are eligible); AST and ALT ≤ 2.5 × ULN (if liver metastases are present, AST/ALT ≤ 5 × ULN); Alkaline phosphatase ≤ 3 × ULN (if liver or bone metastases are present, ALP ≤ 5 × ULN); Albumin ≥ 3 g/dL. 3. Renal function: Serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate by Cockcroft-Gault: Creatinine clearance ≥ 60 mL/min. 4. Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. 9. Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose, must not be breastfeeding, and must agree to use effective contraception for 6 months after the last dose; for male patients with a partner of childbearing potential, effective contraception must be used for 3 months after the last dose; sperm donation is not permitted during the study; 10. Patients are well compliant and agree to cooperate with follow-up.
Exclusion criteria
* 1\. Active or untreated central nervous system (CNS) metastases (e.g., brain or leptomeningeal metastases) as determined by CT or magnetic resonance imaging (MRI) assessment during screening. 2\. Uncontrolled tumor-related pain. 3. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently); patients with an indwelling catheter (e.g., PleurX®) are permitted. 4\. History of a malignancy other than esophageal cancer within 5 years prior to enrollment, except for malignancies with a negligible risk of metastasis or death (e.g., expected 5-year overall survival \> 90%) and those that are expected to be cured after treatment. 5\. History of allergy to monoclonal antibodies, liposomal products, or irinotecan. 6\. Prior or current receipt of any of the following therapies: 1. Use of immunosuppressive medications or systemic corticosteroid therapy for immunosuppressive purposes (dose \> 10 mg/day prednisone or equivalent) within 2 weeks prior to the first dose of study drug; inhaled or topical steroids and adrenal corticosteroid replacement at doses \> 10 mg/day prednisone or equivalent are permitted in the absence of active autoimmune disease. 2. Receipt of a live attenuated vaccine within 4 weeks prior to the first dose of study drug. 3. Major surgery or significant traumatic injury within 4 weeks prior to the first dose of study drug. 7\. Any active autoimmune disease or a history of autoimmune disease. 8. History of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation. 9\. Presence of poorly controlled cardiac clinical symptoms or diseases. 10. Occurrence of a severe infection within 4 weeks prior to the first dose of study drug. 11\. Active pulmonary tuberculosis infection as identified by medical history or CT examination. 12\. Active hepatitis B (HBV DNA ≥ 200 IU/mL or ≥ 1000 copies/mL or ≥ the upper limit of normal), or hepatitis C (positive hepatitis C antibody and HCV RNA above the lower limit of quantification of the assay). 13\. Pregnant or breastfeeding women. 14. Any other condition judged by the investigator that could lead to forced discontinuation from the study, such as other serious illnesses (including mental illnesses) requiring concomitant treatment, alcoholism, drug abuse, family or social factors, or factors that could affect patient safety or compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | through study completion, an average of 12 weeks | Objective response rate (ORR) defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate | through study completion, an average of 12 weeks | Disease Control Rate (DCR) defined as the proportion of patients whose best overall response is CR, PR, or SD. |
| Progression-Free Survival | through study completion, an average of 6 months | Progression-Free Survival defined as the time from the first dose to the first documented disease progression as assessed by the investigator per RECIST version 1.1, or the time from enrollment to death from any cause, whichever occurs first. |
| Oearall survival | through study completion, an average of 12 months | Overall Survival (OS) Defined as the time from the first dose to death from any cause. |
| Safty | Documented from the time of signing the informed consent form until the end of the safety follow-up period (Day 90 after the last dose) or the initiation of a new anti-cancer therapy, whichever occurs first. | Adverse Events (AEs): Incidence and severity (including whether they are serious adverse events or immune-related adverse events), with severity graded according to NCI-CTCAE version 6.0; |
Countries
China
Contacts
CONTACTHaoran Zhai
PRINCIPAL_INVESTIGATORZhigang Li, MD
Shanghai Chest Hospital
Outcome results
None listed